Cannabis use: consistency and validity of self-report, on-site urine testing and laboratory testing

被引:186
作者
Buchan, BJ
Dennis, ML
Tims, FM
Diamond, GS
机构
[1] Operat PAR Inc, St Petersburg, FL 33709 USA
[2] Chestnut Hlth Syst, Bloomington, IL USA
[3] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA
关键词
adolescent drug use; self-reported drug use; urine testing;
D O I
10.1046/j.1360-0443.97.s01.1.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To evaluate the agreement between adolescent self-reported cannabis use, "on-site" qualitative urine screening, and quantitative laboratory testing. Design A cross-sectional study of intake and follow-up data from 248 adolescents entering substance abuse treatment for cannabis use disorders (abuse or dependence). This is part of the multi-site cooperative agreement Cannabis Youth Treatment study. Setting Data collected from adolescents randomly assigned to one of five outpatient treatments at four sites: Operation PAR, Inc., Florida; Chestnut Health Systems, Illinois; University of Connecticut Health Center, Connecticut; and Children's Hospital of Philadelphia, Pennsylvania. Participants The data represent 248 unique individuals from a sample of 297 adolescents ranging in age from 12 to 18 years. Measurements Prevalence, agreement. kappa, sensitivity, specificity, positive and negative predictive value. Findings The self-report rates were higher at intake than either urine test (82.4% vs. 77.0% vs. 52.7%), but both lower and higher at the 3-month follow-up (55.5% vs. 70.0% vs. 47.3%) and 6-month follow-up (60.2% vs. 73.5% vs. 55.8%). The disagreements went in both directions and the kappa coefficients were only in the moderate range (0.4). Over two-thirds of these frequent cannabis users tested positive when they said they had not used in 1 week and one-third tested positive even though they said it had been more than 4 weeks since last use. Conclusions The findings suggest both the advantages of multiple sources of information and the need for further work on the latency of cannabis metabolites in clinical populations.
引用
收藏
页码:98 / 108
页数:11
相关论文
共 45 条
[1]  
*AM SOC ADD MED, 1996, PAT PLAC CRIT TREATM
[2]  
American Psychiatric Association, 2000, Diagnostic and statistical manual of mental disorders, V5th, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
[3]  
BABOR TF, 1990, BEHAV ASSESS, V12, P5
[4]  
Baselt RC., 2008, Disposition of Toxic Drugs and Chemicals in Man, V8
[5]  
BRADLEY BP, 1987, BRIT J ADDICT, V82, P1139
[6]  
CLARK S, 1980, EMIT CANNABINOID ASS, V74
[7]   APPARENT HALF-LIFE OF EXCRETION OF CANNABINOIDS IN MAN [J].
CRIDLAND, JS ;
ROTTANBURG, D ;
ROBINS, AH .
HUMAN TOXICOLOGY, 1983, 2 (04) :641-644
[8]  
DACKIS CA, 1982, AM J PSYCHIAT, V139, P1196
[9]   The Cannabis Youth Treatment (CYT) experiment: rationale, study design and analysis plans [J].
Dennis, M ;
Titus, JC ;
Diamond, G ;
Donaldson, J ;
Godley, SH ;
Tims, FM ;
Webb, C ;
Kaminer, Y ;
Babor, T ;
Roebuck, MC ;
Godley, MD ;
Hamilton, N ;
Liddle, H ;
Scott, CK .
ADDICTION, 2002, 97 :16-34
[10]  
Dennis M., 1999, GLOBAL APPRAISAL IND